FDA approves first new tuberculosis in 40 years

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

The agency approved J&J's pill, Sirturo, for use with other older drugs to fight hard-to-treat .

Sirturo is the first medicine specifically designed for treating multi-drug-resistant tuberculosis. That's an increasingly common form of the disease that cannot be treated with at least two of the four primary antibiotics used to treat tuberculosis.

The standard drugs used to fight the disease were developed in the 1950s and 1960s.

Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug-resistant TB blamed on Indian treatment flaws

Mar 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

tekram
not rated yet Dec 31, 2012
This looks similar to a quinolone drug such as cipro, but it is not. Discovered by Koen Andries and his team at Janssen Pharmaceutica, Bedaquiline was described for the first time in 2004.
Bedaquiline affects the proton pump for ATP synthase, which is unlike the quinolones, whose target is DNA gyrase.